C. Rowan

Determinants of right ventricular ejection fraction in pulmonary arterial hypertension.

S. Bergmann, R. Barst, S. Kawut, 2009, Chest.

Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.

R. Barst, E. Rosenzweig, Laura E Melnick, 2010, The American journal of cardiology.

Fetal infants: the fate of 4172 infants with birth weights of 401 to 500 grams--the Vermont Oxford Network experience (1996-2000).

A. Wilkinson, J. Rogowski, S. Kilpatrick, 2004, Pediatrics.

Ambrisentan for pulmonary arterial hypertension due to congenital heart disease.

E. Rosenzweig, C. Rowan, W. Zuckerman, 2011, The American journal of cardiology.

Abstract 4380: Transition from IV Epoprostenol to Oral/Inhaled Targeted Pulmonary Arterial Hypertension Therapy in Pediatric Idiopathic Pulmonary Arterial Hypertension

R. Barst, E. Rosenzweig, D. Brady, 2008 .

Severe Rhabdomyolysis Due to SARS CoV-2 Infection in a Young Adult

Chloe O. Zimmerman, Christina Johns, C. Rowan, 2020 .

Effects of Chronic IV Epoprostenol on Cardiopulmonary Exercise Testing and Hemodynamics in Children with Idiopathic/Familial Pulmonary Arterial Hypertension.

R. Barst, E. Rosenzweig, S. Zaidi, 2009, ATS 2009.